EXACT Sciences Corporation (NASDAQ:EXAS): 9 analysts have set the short term price target of EXACT Sciences Corporation (NASDAQ:EXAS) at $9.72. The standard deviation of short term price target has been estimated at $3.25, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 14 and $6 respectively.
Many analysts have stated their opinion on the company shares. Major Brokerage house, Mizuho Securities downgrades its ratings on EXACT Sciences Corporation (NASDAQ:EXAS). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on May 4, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, Coward D Scott, officer (SVP and General Counsel) of Exact Sciences Corp, unloaded 1,685 shares at an average price of $6.62 on April 1, 2016. The total amount of the transaction was worth $11,155, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
EXACT Sciences Corporation (NASDAQ:EXAS) : On Monday heightened volatility was witnessed in EXACT Sciences Corporation (NASDAQ:EXAS) which led to swings in the share price. The stock opened for trading at $6.99 and hit $7.2 on the upside , eventually ending the session at $7.04, with a gain of 0.72% or 0.05 points. The heightened volatility saw the trading volume jump to 1,355,582 shares. The 52-week high of the share price is $32.85 and the company has a market cap of $688 million. The 52-week low of the share price is at $4.67 .
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.